Ichnos Glenmark Innovation
Ichnos Glenmark Innovation (IGI) has a mission to provide breakthrough therapies that will extend and improve lives. A clinical-stage biotech with the spirit of a start-up, IGI aims to shift the way the world thinks about innovation through its research and development of transformative multispecific antibody therapies in oncology. Headquartered in New York, IGI is using its patented BEAT® technology platform to advance a pipeline of drug candidates to treat hematologic cancers and solid tumors